Monday, November 9, 2026

USD/EUR Over 1% Down In The Last 21 Sessions

USD/EUR Over 1% Down In The Last 21 Sessions

(VIANEWS) - USD/EUR (USDEUR) has been up by 1.54% for the last 21 sessions. At 22:07 EST on Thursday, 15 June, USD/EUR (USDEUR) is $0.91.

USD/EUR's yearly highs and lows, it's 1.342% up from its 52-week low and 12.851% down from its 52-week high.

Volatility

USD/EUR's last week, last month's, and last quarter's current intraday variation average was a negative 0.30%, a negative 0.04%, and a positive 0.37%, respectively.

USD/EUR's highest amplitude of average volatility was 0.42% (last week), 0.31% (last month), and 0.37% (last quarter), respectively.

Forex Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, USD/EUR's Forex is considered to be overbought (>=80).

News about

  • Usd/jpy falls below the 20-day SMA after US ppi, ahead of the fed. According to FXStreet on Wednesday, 14 June, "The USD/JPY lost over 60 pips during the New York session as the Greenback faced severe selling pressure after Producer Price Index (PPI) data from the US showed lower-than-expected 'factory gate' inflation. ", "In terms of technical analysis, USD/JPY maintains a neutral stance for the short term as indicators turn red on the daily chart. "
  • Usd/jpy looks to build on momentum beyond 141.00, highest since November 2022. According to FXStreet on Thursday, 15 June, "The USD/JPY pair catches aggressive bids during the Asian session on Thursday and touches the 141.00 mark for the first time since November 2022, confirming a breakout through a two-week-old trading range.", "This marks a big divergence in comparison to the BoJ's dovish outlook and acts as a tailwind for the USD/JPY pair."
  • Usd/jpy to see another big fall in the next few months – socgen. According to FXStreet on Wednesday, 14 June, "However, another change is likely in the coming months (we forecast one next month), and if we're also close to the latest peak in US yields, it seems almost inevitable that we'll see another big USD/JPY fall in the next few months."
  • According to FXStreet on Wednesday, 14 June, "This especially benefits the USD against low / falling yielders like JPY and CNH, and helps support our existing USD/JPY 145.00 near-term target and also our view that USD/CNH can rise easily towards 7.30."
  • Usd/jpy price analysis: previous resistance line, fed’s hawkish halt keeps yen bears hopeful past 139.90. According to FXStreet on Wednesday, 14 June, "Even if the quote breaks the 139.90 mark, the 100-bar Exponential Moving Average (EMA) and the monthly bottom, respectively near 139.10 and 138.40, can challenge the USD/JPY sellers.", "In a case where the quote drops past 138.40, the 200-EMA support of 138.00 will act as the last defense of the USD/JPY buyers."

More news about USD/EUR (USDEUR).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biotech Catalyst Season: Regulatory Deadlines and Data Readouts Against Cost Discipline and Slipping Timelines
From late October 2026 to January 2027, mid-cap biotechs cluster pivotal data presentations (ESMO, AHA, AASLD), FDA decision dates (ivonescimab BLA on 2026-11-14, lorundrostat on 2026-12-22) and Q3 earnings. Alongside these, several companies are managing capital: lowering R&D and SG&A guidance, pushing clinical milestones into 2027, authorizing a $400M buyback, and pursuing a delisting. Late-stage programs in oncology, hepatitis delta, hypertension and women's health look near commercial inflection, while cost cuts and delays point to uneven balance-sheet strength.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,996
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,996 facts checked against source5,552 source documents archived
Query this data → isubstrate.com